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Background: Selection of inhaler device type appears to influence real-world effectiveness of
inhaled corticosteroids (ICS), but data are lacking on the role of inhaler device in ICS and long-
acting b2-agonist (LABA) combination therapy for asthma.
Methods: This retrospective matched cohort study compared 1-year asthma outcomes for UK
patients initiating fixed-dose combination (FDC) fluticasoneesalmeterol delivered by pres-
surised metered-dose inhaler (pMDI) versus dry powder inhaler (DPI). Patients with asthma aged
4e80 years receiving a first prescription for FDC fluticasoneesalmeterol by pMDI or DPI were
matched on baseline demographic and asthma severity measures. Co-primary outcomes were
asthma control (a composite measure comprising no recorded hospital attendance for asthma,
oral corticosteroids, or antibiotics for lower respiratory infection) and exacerbation rate.
Results: Compared with the DPI cohort (nZ 1567), patients in the pMDI cohort (nZ 1567) had
significantly greater odds of achieving asthma control during the outcome year (odds ratio [OR]
1.19; 95% confidence interval [CI] 1.01 to 1.40). Exacerbation rate was lower but not signifi-
cantly in the pMDI cohort (adjusted rate ratio for pMDI cohort, 0.82; 95% CI 0.66 to 1.00). The
odds of treatment success (defined as no exacerbations and no change in asthma therapy)
was significantly greater in the pMDI cohort (OR 1.23; 95% CI, 1.07 to 1.42).ademic Primary Care, University of Aberdeen, Foresterhill Health Centre, Westburn Road, Aberdeen
2081233923; fax: þ44 (0) 808 280 0792.
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1458 D. Price et al.Conclusions: For UK primary care patients, pMDIs appear to achieve better asthma control
outcomes than DPIs for delivery of FDC fluticasoneesalmeterol. Pragmatic trials are needed
to further investigate real-world outcomes with different inhaler devices for combination
therapy.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Asthma affects over 300 million people worldwide and has
a substantial impact on patients’ quality of life and on
healthcare resources.1,2 Much of the social and economic
burden of asthma results from poorly controlled disease,
often characterised by asthma exacerbations. International
surveys reveal that asthma is frequently uncontrolled3,4;
thus, much work remains to optimise asthma management,
particularly in the primary care setting where most asthma
care is delivered.5
A challenge for clinicians in providing effective therapy
for asthma is to ensure that patients are using their
inhaler devices correctly. The inhaled route is key for
delivery of bronchodilators as well as inhaled corticoste-
roids (ICS) in persistent asthma. However, many patients
have difficulty using their inhalers, and incorrect inhaler
technique coupled with poor adherence to therapy are
considered common causes of uncontrolled asthma.5e7
Data are currently lacking on the extent of the roles of
inhaler device and technique in delivery of ICS and long-
acting b2-agonist (LABA) combination therapy.
Available inhaler device types for combination therapy
include pressurised metered-dose inhalers (pMDIs) and dry
powder inhalers (DPIs). DPIs are actuated by the patient’s
inhalation, while the pMDIs currently available for combi-
nation therapy require coordination of actuation and inha-
lation. Device preparation and handling vary greatly
according to inhaler brand, particularly among the available
types of DPIs. Some generalisations can be made, however,
with regard to optimal inhalation manoeuvre for each cate-
gory of inhaler. Both require a deep inhalation; with pMDIs
the inhalation should be slow and steady, whereas with DPIs
the inhalation should be sharp and rapid. The very young, the
elderly, and those with severe airway obstruction in partic-
ular may not be able to reproducibly generate an inhalation
rate sufficiently fast for optimal drug delivery with a DPI.7
Conversely, the most common mistake made with a pMDI is
to inhale too fast.7e11 Difficulty with coordination of actua-
tion and inhalation is also common with pMDIs.
Inhaler prescribing practices differ substantially among
countries, with large variation in preferences for pMDIs
versusDPIs, likely influencedbyavailability andhabit, aswell
as by local guidelines. Randomised trials comparing inhalers
for license-equivalent combination ICS-LABA are few and
report similar outcomes with the two types of inhaler
device.12e14 Likewise, for delivery of ICS monotherapy,
comparisons of inhaler device types in randomised controlled
trials indicate no consistent differences among devices in
asthma outcomes; however, most of these trials were con-
ducted to demonstrate equivalence or non-inferiority of
devices for licensing purposes.15e17 Moreover, enrolled
patients were trained and monitored to ensure properinhaler technique, a situation very dissimilar to that in the
real world, where outpatients with asthma commonly make
mistakes with their inhalers.6,18e20 Preliminary data suggest
that selection of inhaler device is associated with real-world
effectiveness of ICS therapy,21,22 but data are lacking on the
role of inhaler device in real-world effectiveness of combi-
nation ICS-LABA therapy.
Database reviews of medical records afford a means of
assessing the effectiveness of interventions in the real-
world clinical setting and provide longer-term outcome
data than are provided by most clinical trials. We undertook
this retrospective database study to compare pMDIs with
DPIs for the delivery of a fixed-dose combination (FDC) of
fluticasone propionate and salmeterol for patients treated
in routine UK primary care. Our objective was to examine
the impact of inhaler device on real-world effectiveness by
comparing the same drug combination delivered by two
different inhaler devices.Methods
Patients and data source
This was a retrospective cohort study using the UK General
Practice Research Database (GPRD). The GPRD is a large,
well-regarded database containing anonymised, longitu-
dinal medical records for approximately 7% of the UK pop-
ulation, contributed by over 500 participating primary care
practices located throughout England, Scotland, Wales, and
Northern Ireland.23 Data from the GPRD are used routinely
in epidemiologic research and in evaluations of respiratory
medications.22,24e28
We studied patients with asthma who had a first
prescription recorded in the GPRD from January 1998 to
June 2007 for FDC fluticasoneesalmeterol delivered by
pMDI (Seretide Evohaler, GlaxoSmithKline) or by DPI (Sere-
tide Accuhaler, GlaxoSmithKline). Eligible patients were
aged 4e80 years at the time of this index prescription (the
index date) and had at least 2 consecutive years’ data in
the GPRD, including a minimum 1-year baseline period
before the index date to establish eligibility and identify
possible confounding factors plus 1 year after the index
date for outcome evaluation.
We identified patients with asthma as those with a diag-
nostic code for asthma in the database or at least two
prescriptions for asthma medications, including at least one
ICS prescription, during the baseline year. Eligible patients
had to be on current therapy, defined as at least one asthma
prescription during the baseline year. The index prescription
was for the initiation of FDC fluticasoneesalmeterol, with
the fluticasone prescribed at either the same or greater dose
relative to the baseline ICS (measured as the beclometasone
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prescription for a separate LABA in addition to ICS were
excluded, as were patients with a diagnostic read code for
any chronic respiratory disease other than asthma (e.g.,
chronic obstructive pulmonary disease). We required that
the period of study for each patient be assessed by the GPRD
as up-to-standard for their primary care practice.
Permission for use of the data was given by the GPRD
Independent Scientific Advisory Committee.
Outcome measures
The two predefined primary outcome measures were
a composite proxy for asthma control and exacerbation rate
during the outcome year. The asthma control measure was
designed to capture available data indicative of control, in
accordance with asthma guidelines and international con-
sensus.29e31 Patients with controlled asthma were defined
as meeting all of the following during the outcome year:
1. no recorded hospital attendance for asthma including
admission, emergency attendance, out-of-hours atten-
dance, or outpatient department attendance, and
2. no acute prescription for oral corticosteroids, and
3. no consultation, hospital admission, or emergency
attendance for lower respiratory tract infection
requiring antibiotics.
Any patient not meeting these three criteria was defined
as having uncontrolled asthma.
An exacerbation was defined as an unscheduled hospital
admission or emergency department attendance for asthma
or acute use of oral corticosteroids.
Secondary outcome measures studied over 1 year after
the index date included another composite measured
treatment successddefined as no exacerbation and no
change in therapy, where a change in therapy could be any
of the following:
1. an increase in dose of ICS,
2. a change in ICS-LABA combination,
3. a change in inhaler device, or
4. use of additional therapy in the form of theophylline or
leukotriene receptor antagonist.
We assessed adherence as the percentage of medication
issued relative to the amount that should have been issued
over the year according to the initial prescribing instructions.
Statistical analyses
All analyses took account of confounding variables using
multiple regression methods. Data were analysed using SPSS
version 17 (SPSS Inc, Chicago, Illinois, USA), STATA version 11
(StataCorp LP, College Station, Texas, USA), and SAS version
9.2 (SAS Software, Ltd, Marlow, Buckinghamshire, UK).
Differences in outcomes between cohorts were considered
significant if p < 0.05 and as trends if 0.05  p < 0.10.
Baseline characteristics were compared between
unmatched treatment cohorts using the ManneWhitney test
for continuous data and c2 test for categorical variables.Baseline differences between treatment cohorts were
considered possibly important if p < 0.10. Variables
meeting this criterion were examined for collinearity as
well as clinical importance to select those used for
regression modelling on outcomes. Continuous variables
showing a skewed distribution were categorised appropri-
ately. We categorised short-acting b2-agonist (SABA) daily
dose (as 0, 1e100, 101e200, 201e300, 301e400, and
>400 mg); prescribed ICS daily dose at the index date and
during the baseline period (as 1e100, 101e250, 251e500,
and >500 mg); and counts of oral corticosteroid prescrip-
tions and hospitalisations (as 0, 1, 2, 3).
The baseline analysis highlighted significant differences
between patients in the two cohorts (see online
Supplemental information). Therefore, we elected to use
two different approachesda matched analysis and an
adjusted but unmatched analysisdto better account for
and examine differences between treatment cohorts in line
with our a priori study protocol.
For the matched analysis, patients were matched at
baseline on a 1:1 basis using key clinically relevant char-
acteristics so as to minimise the potential for confounding
in the outcomes. We matched patients on five baseline
criteria: age, sex, average daily SABA dose, number of oral
corticosteroid prescriptions, and average daily ICS dose.
The former two criteria were chosen to provide comparable
demographic groups; the latter three, as non-collinear
measures of disease severity during the baseline period.
Patient ages were matched within 1 year for those aged
4e5 years, within 3 years for those aged 6e12 years, and
within 5 years for those aged 13 and older.
Comparisons between treatment cohorts were carried
out using conditional logistic and Poisson regression models
to account for patient matching. Odds ratios (ORs) for the
dichotomised definitions of asthma control and treatment
success were calculated using conditional logistic regres-
sion, with control or treatment success as the dependent
variable and inhaler type and residual confounding variables
as explanatory variables. Exacerbation rates in the outcome
period were compared using a conditional Poisson regression
model (using empirical standard errors for more robust
confidence intervals [CIs]), with the number of exacerba-
tions as the dependent variable and inhaler type and residual
confounding variables as explanatory variables. For both
models, variables that remained potentially different on
univariate analysis between thematched cohorts at baseline
(p < 0.10) were included as confounding factors.
For the unmatched analyses, ORs for asthma control and
treatment success were calculated using multiple logistic
regression models, and exacerbation rates were compared
using a Poisson regression model, adjusted for over-
dispersion using robust standard errors (see online
Supplement). All models were adjusted for potential
baseline confounders.
Results
Matched analysis
We identified 3966 patients who were initiated on flutica-
soneesalmeterol by pMDI and 1843 patients initiated on
1460 D. Price et al.fluticasoneesalmeterol by DPI. The matching process
resulted in 1567 patients in each matched treatment cohort
(see Figure in online supplement). Several baseline vari-
ables remained significantly different between cohorts
after matching, but most differences were small and
deemed not clinically meaningful (Tables 1 and 2). Most
patients (95%; Table 2) had a diagnosis of asthma recorded
in the database, and, of the 157 patients without a recor-
ded asthma diagnosis, all had two or more prescriptions for
asthma during the baseline year, and 83% had four or more
during the 2-year study.
Similar numbers of patients in each cohort met the
criteria for asthma control at baseline (Table 2). The year
of the index date was significantly different between
cohorts (p < 0.001; data not shown), generally earlier for
patients receiving a DPI, as DPIs were licensed earlier in the
UK. When differences between matched cohorts were
clinically significant or had a significant effect on the
outcome variable, we adjusted for their effect in the
regression modelling.
Approximately three quarters of patients achieved
asthma control by our composite measure during theTable 1 Baseline demographic and clinical characteristics of a
bination fluticasoneesalmeterol by pressurised metered-dose inh
Characteristic FP-Sal by pMDI (n
Female sex, no. (%) 940 (60.0)
Age, median (IQR) 42 (20e57)
4e11 y, no. (%) 165 (10.5)
12e69 y, no. (%) 1293 (82.5)
70e80 y, no. (%) 109 (7.0)
Weight (kg), mean (SD)b 72.2 (22.7)
Height (m), mean (SD)b 1.62 (0.16)
Body mass index (kg/m2), mean (SD)b 26.7 (7.1)
Socioeconomic status, median (IQR)c 18 (10e33)
Charlson comorbidity index, no. (%)c
0 1382 (88.2)
1 122 (7.8)
2 63 (4.0)
Smoking status, no./total no. (%)
Current 310/1263 (24.5)
Former 271/1263 (21.5)
Never 682/1263 (54.0)
Recorded comorbidity, no. (%)
Rhinitis 329 (21.0)
Cardiac disease 81 (5.2)
Gastroesophageal reflux disease 146 (9.3)
1 þ prescription in 12 mo, no. (%)
NSAID 384 (24.5)
Beta blockerd 69 (4.4)
Paracetamol 376 (24.0)
IQR Z interquartile range; n/a Z p value is not applicable for match
a Conditional logistic regression.
b Not all patients had recorded weight and height data. For weight,
1362 for pMDI versus DPI cohort, respectively.
c Socioeconomic status was that assigned, in quintiles, by the Gener
Multiple Deprivation as a proxy measure. The Charlson comorbidity in
comorbidities, each assigned a score depending on the associated ris
d Most prescribed beta blockers were topical.outcome year (Table 3). The unadjusted OR showed
significantly higher odds of achieving control with flutica-
soneesalmeterol by pMDI than by DPI device (Fig. 1).
Adjustment for confounding factors, including ICS dose at
the index date, did not change the direction or statistical
significance of the result. The exacerbation rate was lower
in the pMDI cohort, although not significantly different
between cohorts (p Z 0.054) (Table 3; Fig. 1).
The odds of meeting the composite measure of treat-
ment success were significantly higher for the pMDI cohort
(Table 3; Fig. 1). Significantly more patients in the DPI
cohort had a change in therapy during the outcome year
(Table 3; Fig. 2). Percentages of patients with increases in
ICS dose or changes in ICS-LABA or inhaler device are
depicted in Fig. 2. Adherence with FDC fluticaso-
neesalmeterol therapy was significantly lower (p Z 0.022)
in the pMDI cohort, as <50% adherence was recorded for
697 [53%] patients in the pMDI cohort and for 633 [49%]
patients in the DPI cohort.
As their device type for SABA reliever therapy during the
outcome year, the majority of patients in both cohorts were
prescribed a pMDI (81% and 51% in pMDI and DPI cohorts,matched population of patients prescribed fixed-dose com-
aler (FP-Sal by pMDI) or dry powder inhaler (DPI).
Z 1567) FP-Sal by DPI (n Z 1567) p valuea
940 (60.0) n/a
44 (19e57) 0.037
188 (12.0) <0.001
1280 (81.7)
99 (6.3)
71.9 (23.0) 0.535
1.62 (0.16) 0.993
26.6 (6.8) 0.535
18 (9e33) 0.725
1387 (88.5) 0.904
109 (7.0)
71 (4.5)
292/1091 (26.8) 0.092
257/1091 (23.6)
542/1091 (49.7)
322 (20.5) 0.760
89 (5.7) 0.514
171 (10.9) 0.130
335 (21.4) 0.027
70 (4.5) 0.928
362 (23.1) 0.552
ing criteria; NSAID Z nonsteroidal anti-inflammatory drug.
nZ 1396 and 1381; height nZ 1474 and 1475; BMI nZ 1380 and
al Practice Research Database to each practice using the Index of
dex is a weighted index that accounts for number and severity of
k of dying.
Table 2 Asthma-related medical resource use during the baseline year for matched population of patients prescribed fixed-
dose combination fluticasoneesalmeterol by pressurised metered-dose inhaler (FP-Sal by pMDI) or dry powder inhaler (DPI).
Characteristic FP-Sal by pMDI (n Z 1567) FP-Sal by DPI (n Z 1567) p valuea
Recorded asthma diagnosis, no. (%) 1498 (95.6) 1479 (94.4) 0.114
Mean SABA dose, no. (%)b
0 60 (3.8) 60 (3.8) n/a
1e100 mg/d 290 (18.5) 290 (18.5)
101e200 mg/d 512 (32.7) 512 (32.7)
201e300 mg/d 222 (14.2) 222 (14.2)
301e400 mg/d 127 (8.1) 127 (8.1)
401 mg/d 356 (22.7) 356 (22.7)
Oral corticosteroid courses, no. (%)
0 1173 (74.9) 1173 (74.9) n/a
1 290 (18.5) 290 (18.5)
2 66 (4.2) 66 (4.2)
3e5 38 (2.4) 38 (2.4)
Total exacerbations, no. (%)c
0 1173 (74.9) 1170 (74.7) 0.234
1 289 (18.4) 292 (18.6)
2 67 (4.3) 67 (4.3)
3 38 (2.4) 38 (2.4)
Mean ICS dose during baseline year, no. (%)
None 52 (3.3) 52 (3.3) n/a
1e199 mg/d 819 (52.3) 819 (52.3)
200e399 mg/d 394 (25.1) 394 (25.1)
400e599 mg/d 141 (9.0) 141 (9.0)
600e799 mg/d 79 (5.0) 79 (5.0)
800e1199 mg/d 59 (3.8) 59 (3.8)
1200e1599 mg/d 13 (0.8) 13 (0.8)
1600 mg/d 10 (0.6) 10 (0.6)
Spacer device used, no. (%) 326 (20.8) 206 (13.1) <0.001
Mixed ICS device typesdbaseline yr, no. (%) 76 (5.0) 121 (8.0) 0.001
ICS device type during baseline yr, no. (%)
pMDI 1221 (77.9) 761 (48.6) <0.001
Breath-actuated MDI 217 (13.8) 369 (23.5)
DPI 77 (4.9) 386 (24.6)
None/missing data 52 (3.3) 51 (3.3)
ICS dose at index date, no. (%)
1e200 mg/d 51 (3.3) 57 (3.6) <0.001
201e500 mg/d 499 (31.8) 669 (42.7)
501e1000 mg/d 718 (45.8) 636 (40.6)
1000 mg/d 299 (19.1) 205 (13.1)
Asthma consultations, no. (%)
0 469 (29.9) 452 (28.8) <0.001
1 508 (32.4) 472 (30.1)
2 311 (19.8) 300 (19.1)
3 279 (17.8) 343 (21.9)
Courses of antibiotics for lower respiratory
tract infection, no. (%)
0 1218 (77.7) 1203 (76.8) 0.750
1 248 (15.8) 268 (17.1)
2 101 (6.4) 96 (6.1)
1 Hospitalisation for asthma, no. (%) 1 (0.1) 3 (0.2) 0.306
Asthma control status, no. (%)d 968 (61.8) 970 (61.9) 0.913
ICS Z inhaled corticosteroid; n/a Z p value is not applicable for matching criteria; SABA Z short-acting b2-agonist.
a Conditional logistic regression.
b The SABA dose is the albuterol dose equivalent (standard dose in UK is 100 mg). The ICS dose is the chlorofluorocarbon-beclome-
thasone dose equivalent.
c An exacerbation was defined as an occurrence of unscheduled hospital admission or emergency room attendance for asthma or
prescription for oral corticosteroids; exacerbations on the index date were included in the baseline data.
d Asthma control was defined as no recorded hospital attendance for asthma, oral corticosteroid course, or antibiotics for lower
respiratory infection.
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Table 3 Outcomes over 1 year after prescription for fixed-dose combination fluticasoneesalmeterol by pressurised metered-
dose inhaler (FP-Sal by pMDI) or dry powder inhaler (DPI).
Outcome FP-Sal by pMDI (n Z 1567) FP-Sal by DPI (n Z 1567) p valuea
Asthma control,b no. (%) 1176 (75.0) 1127 (71.9)
Treatment success, no. (%) 896 (57.2) 815 (52.0)
Asthma exacerbations,c no. (%)
0 1329 (84.8) 1289 (82.3) 0.054
1 169 (10.8) 201 (12.8)
2 44 (2.8) 46 (2.9)
3 25 (1.6) 31 (2.0)
Asthma consultations, median (IQR) 0 (0e1) 0 (0e2) <0.001
SABA daily dose (mg), median (IQR) 164 (55e329) 164 (55e329) 0.648
Average ICS daily dose (mg) 0 1 (0.1) 0 (0) 0.390
1e99 379 (24.2) 412 (26.3)
100e199 329 (21.0) 344 (22.0)
200e299 266 (17.0) 257 (16.4)
300e399 167 (10.7) 120 (7.7)
400e599 268 (17.1) 255 (16.3)
600e799 81 (5.2) 95 (6.1)
800 76 (4.9) 84 (5.4)
Disaggregated outcomes of the composite
measures
1 hospital admission, no. (%) 1 (0.0) 1 (0.0) 1.0
1 oral corticosteroid course, no. (%) 238 (15.2) 278 (17.7) 0.051
1 course of antibiotics for LRTI, no. (%) 236 (15.1) 261 (16.7) 0.209
1 change in therapy, no. (%) 548 (35.0) 616 (39.3) 0.011
ICS Z inhaled corticosteroid; IQR Z interquartile range; LRTI Z lower respiratory tract infection; SABA Z short-acting b2-agonist.
a Conditional logistic regression.
b Asthma control was defined as no recorded hospital attendance for asthma, oral corticosteroid course, or antibiotics for lower
respiratory infection.
c An exacerbation was defined as an occurrence of unscheduled hospital admission or emergency room attendance for asthma or
prescription for oral corticosteroids.
1462 D. Price et al.respectively); 14% and 24%, respectively, received a breath-
actuated MDI; and the remainder (4% and 22%, respectively)
a DPI (1% and 2% received no SABA prescription during the
outcome year).0.5 1 2
Treatment success, 
unadjusted OR* (95% CI)
1.23 (1.07, 1.42)
Exacerbations, 
adjusted RR† (95% CI) 0.82 (0.66, 1.00)
Primary measure of asthma control, 
unadjusted OR* (95% CI)
1.19 (1.01, 1.40)
Figure 1 ORs for asthma control and treatment success, and
RR for exacerbations, for the pMDI cohort. Data represent
outcomes for patients in the pMDI cohort as comparedwith those
inDPI cohort (ORs andRRof 1.0) over 1 year after prescription for
fixed-dose combination fluticasoneesalmeterol.)No significant
effects (ie, no confounders identified). yadjusted for baseline
confounders and inhaled corticosteroid dose at the index date.
ORZ odds ratio; RRZ rate ratio; pMDIZ pressurised metered
dose inhaler; DPIZ dry powder inhaler.Unmatched analysis
Baseline data and outcomes for the unmatched pMDI and DPI
cohorts are summarised in the online supplement
(Supplemental Tables 1e4). The adjusted odds ratio for
achieving asthma control was significantly higher, and exac-
erbation rate ratio significantly lower, for patients prescribed
a pMDI (Supplemental Table 4).Discussion
In this real-world observational study, the proportion of
patients meeting the asthma control criterion increased
from baseline in both cohorts receiving FDC therapy with
fluticasone and salmeterol for 1 year. Asthma control over
the outcome year was more likely for the patients who
initiated combination therapy by pMDI rather than by DPI.
The exacerbation rate ratio trended in the same direction
as the control measure, as exacerbations were less
frequent in the pMDI cohort, although the difference in
exacerbation rates was not statistically significant. The
likelihood of patients meeting the composite measure of
treatment success (which incorporated the absence of
exacerbations as well as no change in asthma therapy) was
significantly greater in the pMDI cohort.
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Figure 2 Percentage of patients with change in therapy during the outcome year. )p Z 0.011 for overall comparison between
treatment cohorts. No patients in either cohort were prescribed additional asthma therapy. FP-Sal Z fluticasoneesalmeterol;
pMDIZ pressurised metered dose inhaler; DPIZ dry powder inhaler; ICSZ inhaled corticosteroid; LABAZ long-acting b2-agonist.
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and exacerbation measures could be explained by the fact
that asthma control is a dichotomy (yes versus no) and thus
one hospitalisation, corticosteroid prescription, or antibi-
otic use is effectively the same as 100. Instead, the exac-
erbation rate is a continuum and thus distinguishes
between 1 and 100 ‘events’. Moreover, the composite
measure of asthma control was constructed to capture
antibiotic prescribing for lower respiratory tract infection,
together with oral corticosteroids and unplanned visits or
hospitalisations for asthma, because treatment with anti-
biotics is commonly reported for patients presenting for
acute asthma exacerbations.32,33
The findings of this study reflect the real-world
outcomes of therapy with FDC fluticasoneesalmeterol for
asthma. Different from the perspective of a randomised
controlled trial, where patient progress is closely moni-
tored and treatment adherence encouraged, a database
assessment such as this one captures the effects of actual
prescribing practices and takes into account patient and
physician preferences, patient education, and adherence
with therapy (or lack thereof). This enabled us to study the
comparative effectiveness of inhaler devices as used by
real-world patients in real-world settings. Our main analysis
matched patients at baseline for demographic and asthma-
related characteristics to provide a more rigorous
comparison of the effects of therapy for patients with
similar asthma severity at baseline. Because patient
subgroups could potentially be excluded by the matching
process, we also performed an unmatched analysis
adjusted for confounders, the results of which were similar
to and thus provide support for the matched analyses.
The effectiveness of inhaled therapy depends not only
on the drug(s) delivered, but also, and perhaps more
importantly, on the delivery device and the patient’s ability
to use it correctly. We can only speculate why pMDIs were
associated with better asthma control outcomes than DPIs
for FDC fluticasoneesalmeterol. It is important to note that
DPIs are prescribed less frequently than pMDIs in the UK,
a fact supported by our finding of more patients with
a recorded prescription for a pMDI at baseline and on theindex date. Thus, it is possible there may be a prescribing
preference that biases the type of patient for whom DPIs
are prescribed. We tried to eliminate any such bias by
matching patients on demographic characteristics and
baseline characteristics indicative of asthma severity and
control, with statistical adjustments for any remaining
confounding factors. While matching is never perfect, we
believe the process addressed baseline differences as
completely as was feasible without over-matching or losing
too many patient numbers.
As DPIs are prescribed less frequently in the UK, it is
possible that the differences between inhaler cohorts arose
because UK practitioners are less proficient at teaching DPI
technique. Another possibility is that patients prescribed
a pMDI were still using it because they could use it properly,
whilst those in the DPI cohort had been switched because of
poor pMDI technique, and they also had poor DPI technique.
This theory is supported by the fact that 80% of patients in
the pMDI cohort were prescribed a pMDI device for ICS
during the baseline year, while only 25% of patients in the
DPI cohort were prescribed a DPI device at baseline.
Therefore, on the index date, less than one fifth of patients
in the pMDI cohort had a device switch, whilst three quar-
ters of patients in the DPI cohort had a device switch from
a pMDI or a breath-actuated MDI to a DPI for FDC flutica-
soneesalmeterol therapy.
In addition, patients in the DPI cohort were more likely
to have mixed inhaler types for maintenance and reliever
therapies during the outcome year and thus could have
confused inhaler technique because of switching between
devices. Our ability to separate out the role of mixing
device types from that of the ICS-LABA device itself was
limited by the high correlation (and subsequent collin-
earity) between ICS-LABA device type used and use of same
versus mixed devices for reliever therapy. However, an
earlier study looking at the effect of prescribing mixed
inhaler types for maintenance and reliever therapies
reported a higher percentage of patients making inhaler
technique errors where pMDI and DPI devices were used in
combination as compared with use of two different DPI
devices.34
1464 D. Price et al.Another possibility, purely speculative, is that the
additional benefit of the bronchodilator in the combination
might have helped patients who made mistakes with their
ICS monotherapy pMDI to recognise their coordination
issues, and this helped them to improve their inhalation
technique with the FDC pMDI. In theory, of course, the
presence of the bronchodilator would also help patients to
self-train with a DPI, although their ability to generate the
correct inspiratory acceleration and velocity with a DPI
would remain a limiting factor.
Other possible explanations for the differences between
cohorts seem less likely. While the index date ICS dose was
higher in the pMDI cohort, the average ICS dose during the
outcome year was similar in the two cohorts; moreover,
adjusting for index ICS dose did not significantly affect
outcomes. Better adherence in the pMDI cohort can be
ruled out as a possibility because, in fact, adherence was
worse in the pMDI than the DPI cohort. Overall, approxi-
mately half of patients showed <50% adherence. Poor
levels of adherence with asthma maintenance therapy have
been recorded in all real-world studies on this topic.35e39
The apparent superiority of pMDI in producing better
asthma control with FDC fluticasoneesalmeterol was an
unexpected finding. In a prior, similarly designed cohort
study, we found that DPIs were consistently more effective
than pMDIs for patients initiating ICS monotherapy.22 It is
possible that, in the present study, the LABA in the pMDI
drove better technique or the effects of device mixing were
more prominent. Randomised trials comparing pMDIs and
DPIs for FDC fluticasoneesalmeterol report similar
outcomes with the two types of inhaler device.12e14 The
differences between cohorts in the present study, while
statistically significant, were not large, as reflected in the
relatively low odds ratios. In cross-sectional observational
studies of inhaler technique, no clear pattern emerges:
patients assessed in the clinic make mistakes of different
types and to varying degrees with both pMDIs and
DPIs.9,19,40e44
The use of a large database has enabled us to study real-
world outcomes with asthma inhaler devices in a represen-
tativeUKprimary carepopulation.We studiedoutcomes over
a full year to balance seasonal influences on outcome
measures. A major limitation of this study, inherent to
observational studies, is the possibility of unrecognised
confounding factors or influences onprescribing thatwehave
not accounted for, e.g., inhaler technique, and, as for any
retrospective study, the analyses are susceptible to bias.
While the GPRD is a well-validated and well-maintained
database, we cannot rule out the possibility of inaccurate or
missing data. Moreover, study analyses are based on recor-
dedprescriptions for FDC salmeterolefluticasone;we cannot
be certain thatmedicationswere actually dispensed or taken
as prescribed. Finally, only one type of DPI was evaluated in
this study; thus, our findings apply to the pMDI-Accuhaler
comparison and may not be applicable to other types of DPI.Conclusions
In this retrospective database analysis, asthma control and
treatment success were significantly more likely for
primary care patients who were prescribed a pMDI ratherthan a DPI device for a fixed-dose combination of flutica-
soneesalmeterol. Exacerbations were less frequent in the
pMDI cohort but not statistically different between cohorts.
For real-world ICS-LABA FDC therapy in the UK, pMDIs
appear to achieve better asthma control outcomes than
DPIs for delivery of FDC fluticasoneesalmeterol. Despite
careful matching and adjustments, an effect of confound-
ing factors such as baseline severity cannot be ruled out.
Therefore, pragmatic trials are required to investigate
real-world outcomes with different inhaler devices for
combination therapy. In addition, further work remains to
investigate the effects of device mixing and practice
preferences on inhaler technique and asthma-related
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